444 | A PHASE 1 STUDY OF SGR‐1505, AN ORAL, POTENT MALT1 INHIBITOR FOR R/R B‐CELL MALIGNANCIES, INCLUDING CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
Hematological Oncology · 2025-06 · 43 (S3)
DOI: 10.1002/hon.70094_444 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 15.06.2025. Verfasst von V. Musteata und 14 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Musteata, V., Spurgeon, S., Karnabeda, O., Di, M., Gabrail, N., Murthy, G. S. G., Yin, W., Upalawanna, A., Zhang, S., Gupta, V., Yoo, B., Basile, F. G., Dugan, M., Ulrickson, M., & Olszewski, A. (2025). 444 | A PHASE 1 STUDY OF SGR‐1505, AN ORAL, POTENT MALT1 INHIBITOR FOR R/R B‐CELL MALIGNANCIES, INCLUDING CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL). Hematological Oncology, 43(S3). https://doi.org/10.1002/hon.70094_444
Vancouver
Musteata V, Spurgeon S, Karnabeda O, Di M, Gabrail N, Murthy GSG, et al. 444 | A PHASE 1 STUDY OF SGR‐1505, AN ORAL, POTENT MALT1 INHIBITOR FOR R/R B‐CELL MALIGNANCIES, INCLUDING CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL). Hematological Oncology. 2025;43(S3). doi:10.1002/hon.70094_444
BibTeX
@article{Musteata2025,
author = {Musteata, V. and Spurgeon, S. and Karnabeda, O. and Di, M. and Gabrail, N. and Murthy, G. S. Guru and Yin, W. and Upalawanna, A. and Zhang, S. and Gupta, V. and Yoo, B. and Basile, F. G. and Dugan, M. and Ulrickson, M. and Olszewski, A.},
title = {444 | A PHASE 1 STUDY OF SGR‐1505, AN ORAL, POTENT MALT1 INHIBITOR FOR R/R B‐CELL MALIGNANCIES, INCLUDING CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)},
journal = {Hematological Oncology},
year = {2025},
volume = {43},
number = {S3},
doi = {10.1002/hon.70094_444}
}
EUVIMED